Annexon is a biopharmaceutical company that focuses on therapeutics for autoimmune, neurodegenerative, and ophthalmic conditions. The company's product candidates target specific disease processes, including antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Annexon's investigational products include monoclonal antibodies and oral small molecules that are currently in clinical trials for various conditions.